SINGH BROTHERS FINED RS 2,600 CR FOR HIDING FACTS FROM DAIICHI

New Delhi, Medicare News, May 15, 2016

Billionaire businessman Malvinder Mohan Singh and his younger brother Shivinder Mohan Singh have been fined nearly Rs 2,600 crore, media reports say.
The erstwhile promoters of drug maker Ranbaxy were penalised for concealing and misrepresenting facts from Japanese pharmaceutical company, Daiichi Sankyo about its 2008 deal involving the sale of controlling stake in Ranbaxy.

The fine was decided by Singapore International Arbitration Centre (SIAC), which heard an arbitration case filed by Daiichi Sankyo in 2013. The Singh brothers, former Ranbaxy owners, had sold their stake to Daiichi Sankyo for $2.4 billion in 2008.

Japanese drugmaker Daiichi Sankyo later sold Ranbaxy to Mumbai-based Sun Pharma. The Singh brothers now run hospitals under the Fortis brand. They also own financial services firm Religare Enterprises.

Related Posts

13 Years after Oxytocin Order, HC Seeks Compilance Status

GWALIOR: The Gwalior Bench of the Madhya Pradesh High Court has directed the state government to submit a comprehensive compliance status report. This order addresses the implementation of the court’s…

Centre Pushes Haryana to Fast-Track AIIMS Rewari

New Delhi | August 18, 2025 — The Union government has urged Haryana to speed up work on AIIMS Rewari (Majra) and resolve on-ground hurdles so the institute can open…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

Mankind Pharma to Acquire 70% Stake in Belgium’s ACTx

Can a drug licence be suspended before a hearing? Karnataka HC explains rule

Can a drug licence be suspended before a hearing? Karnataka HC explains rule

A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

A Boy survives 18th Floor Fall, thanks to Yashoda Medicity

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs